William King - Dec 31, 2021 Form 5 Insider Report for DANAHER CORP /DE/ (DHR)

Role
SVP, Strategic Development
Signature
/s/ James F. O'Reilly, attorney-in-fact for William King
Stock symbol
DHR
Transactions as of
Dec 31, 2021
Transactions value $
$14,613
Form type
5
Date filed
1/31/2022, 04:11 PM
Next filing
Feb 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DHR Danaher Deferred Compensation Programs - Danaher Stock Fund +Grant/Award $3,160 +13 +0.07% $237.84 18,205 Jan 29, 2021 Common Stock 13 $0.00 Direct F1, F2, F3
transaction DHR Danaher Deferred Compensation Programs - Danaher Stock Fund +Grant/Award $3,815 +15 +0.08% $253.94 18,205 Apr 30, 2021 Common Stock 15 $0.00 Direct F1, F2, F3
transaction DHR Danaher Deferred Compensation Programs - Danaher Stock Fund +Grant/Award $3,818 +13 +0.07% $297.49 18,205 Jul 30, 2021 Common Stock 13 $0.00 Direct F1, F2, F3
transaction DHR Danaher Deferred Compensation Programs - Danaher Stock Fund +Grant/Award $3,820 +12 +0.07% $311.77 18,205 Oct 29, 2021 Common Stock 12 $0.00 Direct F1, F2, F3

Explanation of Responses:

Id Content
F1 The reported securities are notional dividend accruals on phantom shares in the Danaher stock fund under one of the plans that form part of Danaher's deferred compensation program. The number of phantom shares accrued as a result of such notional dividend accruals is based on the closing price of Danaher common stock as reported on the NYSE on the date such dividend accruals are credited to the fund, which is the price shown in Table II, Column 8 above.
F2 The notional shares convert on a one-for-one basis.
F3 The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission.